Bismuth Absorption from205Bi-Labelled Pharmaceutical Bismuth Compounds Used in the Treatment of Peptic Ulcer Disease
- 1 January 1992
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 27 (4) , 333-336
- https://doi.org/10.3109/00365529209000083
Abstract
The absorption of bismuth from five 205Bi-labelled pharmaceutically used bismuth compounds was studied in man. From single oral doses of all compounds under investigation only less than 0.1% bismuth was absorbed and excreted with the urine. A significantly higher absorption was observed from the colloidal bismuth subcitrate (0.042% of the dose) and the basic bismuth gallate (0.038%) than from the basic bismuth salicylate, nitrate, and aluminate (0.005-0.002%). No retention of bismuth in the whole body was found from the single dose experiment. The biologic fast-term half-lives of absorbed bismuth were calculated to be 0.12 and 1.5 days.Keywords
This publication has 9 references indexed in Scilit:
- Bioavailability of bismuth from205Bi-labelled pharmaceutical oral Bi-preparations in ratsArchives of Toxicology, 1991
- Pharmakokinetik von Wismut-Präparaten bei Patienten mit Gastritis und UlkuskrankheitJournal of Molecular Medicine, 1990
- Bismuth Subsalicylate: History, Chemistry, and SafetyClinical Infectious Diseases, 1990
- Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthateEuropean Journal of Clinical Pharmacology, 1989
- Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1985
- Pyloric Campylobacter infection and gastroduodenal diseaseThe Medical Journal of Australia, 1985
- Cinétique et distribution du 206Bi chez le rat et le lapin: un modèleThe International Journal of Applied Radiation and Isotopes, 1983
- Bismuth nephrotoxicityThe American Journal of Medicine, 1964